Premium
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Author(s) -
Mughal Tariq I.,
Pemmaraju Naveen,
Psaila Bethan,
Radich Jerald,
Bose Prithviraj,
Lion Thomas,
Kiladjian JeanJacques,
Rampal Raajit,
Jain Tania,
Verstovsek Srdnan,
Yacoub Abdulraheem,
Cortes Jorge E.,
Mesa Ruben,
Saglio Giuseppe,
Etten Richard A.
Publication year - 2020
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2771
Subject(s) - myelofibrosis , medicine , myeloid leukemia , ruxolitinib , myeloproliferative disorders , tyrosine kinase , hematology , haematopoiesis , oncology , cancer research , stem cell , bioinformatics , biology , receptor , bone marrow , genetics
Abstract This review reflects the presentations and discussion at the 14th post‐American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single‐cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR‐ABL 1 mutant subclones following ABL 1‐tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK‐STAT and the merits of integrating activin receptor ligand traps, interferon‐α, and allografting in the current treatment algorithm for patients with myelofibrosis.